vs
AC Immune SA(ACIU)与Arcellx, Inc.(ACLX)财务数据对比。点击上方公司名可切换其他公司
Arcellx, Inc.的季度营收约是AC Immune SA的1.2倍($1.7M vs $1.4M)。AC Immune SA净利率更高(-1622.4% vs -3513.4%,领先1891.0%)。AC Immune SA同比增速更快(90.1% vs -89.2%)
AC Immune SA是一家临床阶段生物制药企业,专注于开发阿尔茨海默病、帕金森病及罕见tau蛋白病等神经退行性疾病的创新疗法与诊断方案,与全球领先药企展开合作,致力于满足神经疾病领域未被满足的临床需求。
Arcellx, Inc.是一家处于临床阶段的生物技术企业,专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法,其核心管线针对肿瘤领域未被满足的医疗需求,服务全球患者群体。
ACIU vs ACLX — 直观对比
营收规模更大
ACLX
是对方的1.2倍
$1.4M
营收增速更快
ACIU
高出179.3%
-89.2%
净利率更高
ACIU
高出1891.0%
-3513.4%
损益表 — Q2 2025 vs Q4 2025
| 指标 | ||
|---|---|---|
| 营收 | $1.4M | $1.7M |
| 净利润 | $-23.3M | $-58.1M |
| 毛利率 | — | — |
| 营业利润率 | -1484.5% | -3850.2% |
| 净利率 | -1622.4% | -3513.4% |
| 营收同比 | 90.1% | -89.2% |
| 净利润同比 | 6.9% | -23.4% |
| 每股收益(稀释后) | — | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ACIU
ACLX
| Q4 25 | — | $1.7M | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | $1.4M | $7.6M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | — | $26.0M | ||
| Q2 24 | $755.7K | $27.4M | ||
| Q1 24 | — | $39.3M |
净利润
ACIU
ACLX
| Q4 25 | — | $-58.1M | ||
| Q3 25 | — | $-55.8M | ||
| Q2 25 | $-23.3M | $-52.8M | ||
| Q1 25 | — | $-62.3M | ||
| Q4 24 | — | $-47.1M | ||
| Q3 24 | — | $-25.9M | ||
| Q2 24 | $-25.0M | $-27.2M | ||
| Q1 24 | — | $-7.2M |
营业利润率
ACIU
ACLX
| Q4 25 | — | -3850.2% | ||
| Q3 25 | — | -1248.3% | ||
| Q2 25 | -1484.5% | -777.4% | ||
| Q1 25 | — | -847.6% | ||
| Q4 24 | — | -348.2% | ||
| Q3 24 | — | -129.1% | ||
| Q2 24 | -3051.1% | -127.8% | ||
| Q1 24 | — | -40.3% |
净利率
ACIU
ACLX
| Q4 25 | — | -3513.4% | ||
| Q3 25 | — | -1127.1% | ||
| Q2 25 | -1622.4% | -698.6% | ||
| Q1 25 | — | -766.0% | ||
| Q4 24 | — | -308.4% | ||
| Q3 24 | — | -99.4% | ||
| Q2 24 | -3313.0% | -99.3% | ||
| Q1 24 | — | -18.3% |
每股收益(稀释后)
ACIU
ACLX
| Q4 25 | — | $-1.01 | ||
| Q3 25 | — | $-0.99 | ||
| Q2 25 | — | $-0.94 | ||
| Q1 25 | — | $-1.13 | ||
| Q4 24 | — | $-0.87 | ||
| Q3 24 | — | $-0.48 | ||
| Q2 24 | — | $-0.51 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $28.3M | $450.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $82.2M | $402.4M |
| 总资产 | $209.2M | $604.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
ACIU
ACLX
| Q4 25 | — | $450.3M | ||
| Q3 25 | — | $461.4M | ||
| Q2 25 | $28.3M | $453.1M | ||
| Q1 25 | — | $543.3M | ||
| Q4 24 | — | $587.4M | ||
| Q3 24 | — | $574.3M | ||
| Q2 24 | $56.7M | $516.7M | ||
| Q1 24 | — | $573.9M |
股东权益
ACIU
ACLX
| Q4 25 | — | $402.4M | ||
| Q3 25 | — | $440.8M | ||
| Q2 25 | $82.2M | $392.2M | ||
| Q1 25 | — | $416.9M | ||
| Q4 24 | — | $454.8M | ||
| Q3 24 | — | $483.0M | ||
| Q2 24 | $135.8M | $487.2M | ||
| Q1 24 | — | $496.6M |
总资产
ACIU
ACLX
| Q4 25 | — | $604.0M | ||
| Q3 25 | — | $655.9M | ||
| Q2 25 | $209.2M | $619.1M | ||
| Q1 25 | — | $648.1M | ||
| Q4 24 | — | $711.3M | ||
| Q3 24 | — | $764.9M | ||
| Q2 24 | $261.3M | $734.3M | ||
| Q1 24 | — | $779.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | — | $-58.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-58.9M |
| 自由现金流率自由现金流/营收 | — | -3563.4% |
| 资本支出强度资本支出/营收 | — | 46.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-212.6M |
8季度趋势,按日历期对齐
经营现金流
ACIU
ACLX
| Q4 25 | — | $-58.2M | ||
| Q3 25 | — | $-49.2M | ||
| Q2 25 | — | $-39.7M | ||
| Q1 25 | — | $-63.1M | ||
| Q4 24 | — | $-46.0M | ||
| Q3 24 | — | $30.7M | ||
| Q2 24 | — | $-36.2M | ||
| Q1 24 | — | $-31.9M |
自由现金流
ACIU
ACLX
| Q4 25 | — | $-58.9M | ||
| Q3 25 | — | $-49.5M | ||
| Q2 25 | — | $-40.2M | ||
| Q1 25 | — | $-63.9M | ||
| Q4 24 | — | $-47.5M | ||
| Q3 24 | — | $28.4M | ||
| Q2 24 | — | $-39.5M | ||
| Q1 24 | — | $-38.3M |
自由现金流率
ACIU
ACLX
| Q4 25 | — | -3563.4% | ||
| Q3 25 | — | -1000.3% | ||
| Q2 25 | — | -532.4% | ||
| Q1 25 | — | -786.4% | ||
| Q4 24 | — | -311.3% | ||
| Q3 24 | — | 109.2% | ||
| Q2 24 | — | -144.1% | ||
| Q1 24 | — | -97.7% |
资本支出强度
ACIU
ACLX
| Q4 25 | — | 46.2% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | — | 8.8% | ||
| Q2 24 | — | 11.7% | ||
| Q1 24 | — | 16.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图